Phaseline

Targets › POLR2A

POLR2A (DNA-directed RNA polymerase II subunit RPB1): drug programs, companies and trials

15 programs from 13 companies in 27 trials: 9 Phase 4, 8 Phase 1, 5 Phase 2, 5 Phase 3; Infectious disease, Oncology, Genitourinary; next expected readout Dec 2026.

Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. (UniProt, P24928)

Open in Phaseline: the race on POLR2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Instituto Mexicano del Seguro SocialDarunavir
Human immunodeficiency virus type 1 protease inhibitor
PROT, CYP3A4, POLR2APhase 4HIV InfectionDec 2026
Harvard School of Public Health (HSPH)DTG/ABC/3TC
Integrase strand transfer inhibitor (dolutegravir) combined with nucleoside reverse transc
INTEGRASE, ABCC4, POLR2APhase 4HIVDec 2026
Kirby InstituteSofosbuvir
RNA-directed RNA polymerase inhibitor
POLR2APhase 4Hepatitis CJul 2029
Jiangsu Hansoh PharmaceuticalTenofovir Amibufenamide (TMF)
Nucleotide reverse transcriptase inhibitor (NRTi) - prodrug of tenofovir
POLR2APhase 4Hepatitis B, ChronicSep 2029
José Antonio Mata MarínDTG/3TC
Integrase strand transfer inhibitor (INSTI) + nucleoside reverse transcriptase inhibitor (
INTEGRASE, POLR2APhase 4HIV Infections–
Luye Pharma GroupLurbinectedin
RNA polymerase II inhibitor; RNA-dependent transcription inhibitor
POLR2APhase 3Relapsed Small Cell Lung CancerDec 2027
Gilead SciencesEmtricitabine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2A, POLR1CPhase 3Pre-Exposure Prophylaxis of HIV Infection; Hiv; Alcohol Use, Unspecified; Pre-exposure Prophylaxis …Jan 2028
GSKRPV ULA
Non-nucleoside reverse transcriptase inhibitor (ultra-long-acting formulation)
POLR2APhase 3HIV InfectionsSep 2029
Africa Health Research InstituteDapivirine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2APhase 3HIV Infections–
Merck & Co. (MSD)ISL/ULO
fixed-dose combination of nucleoside reverse transcriptase translocation inhibitor and non
POLR2APhase 2Human Immunodeficiency Virus Type 1 (HIV-1) InfectionFeb 2029
Harvard School of Public Health (HSPH)Nevirapine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2APhase 2HIVJun 2029
Harvard School of Public Health (HSPH)Zidovudine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2APhase 2HIVJun 2029
National Cancer Institute (NCI)Pidnarulex
RNA Polymerase I inhibitor
POLR2A, POLR1APhase 1Metastatic Malignant Solid Neoplasm; Metastatic Colorectal Adenocarcinoma; Anatomic Stage III Breast Cancer AJCC v8; Burkitt LymphomaDec 2026
Senhwa BiosciencesCX-5461
POLR2A/POLR1A inhibitor; transcription inhibitor targeting ribosomal RNA synthesis
POLR2A, POLR1APhase 1Advanced Solid TumorMar 2027
Henan Genuine BiotechRo-0622
Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2APhase 1Renal Insufficiency–

Conditions

HIV Infections (3) HIV (3) HIV Infection (2) Pre-Exposure Prophylaxis of HIV Infection (2) Metastatic Malignant Solid Neoplasm (1) Metastatic Colorectal Adenocarcinoma (1) Anatomic Stage III Breast Cancer AJCC v8 (1) Burkitt Lymphoma (1) Renal Insufficiency (1) Advanced Solid Tumor (1) Relapsed Small Cell Lung Cancer (1) Hepatitis B, Chronic (1)

Modalities

small molecule (14), mixed (1)

Companies

Harvard School of Public Health (HSPH) (3) Instituto Mexicano del Seguro Social (1) José Antonio Mata Marín (1) National Cancer Institute (NCI) (1) Henan Genuine Biotech (1) Senhwa Biosciences (1) Luye Pharma Group (1) GSK (1) Jiangsu Hansoh Pharmaceutical (1) Kirby Institute (1) Gilead Sciences (1) Africa Health Research Institute (1) Merck & Co. (MSD) (1)

Related targets

INTEGRASE (2) POLR1A (2) PROT (1) CYP3A4 (1) POLR1C (1) ABCC4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.